Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
On November 9, 2022, AbbVie (NYSE: ABBV) announced its participation in the 4th Annual Wolfe Research Healthcare Conference scheduled for November 15, 2022, at 10:30 a.m. CT. Key executives, including Rob Michael and Jeffrey Stewart, will present virtually. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later that day. AbbVie focuses on innovative medicines in various therapeutic areas, such as immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) will present 36 abstracts at the American College of Rheumatology's annual meeting (ACR Convergence 2022), highlighting advancements in treatments for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Key data includes long-term safety analyses for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab). Notable presentations cover major adverse cardiovascular events in clinical trials and the impact of second-line therapies on disease control. These findings underscore AbbVie's ongoing commitment to innovation in rheumatology.
AbbVie announced results from its NOVA phase 2 study evaluating AGN-151607 for preventing postoperative atrial fibrillation (POAF) in cardiac surgery patients. Although the primary endpoint was not met, the data indicated a significant 29% relative risk reduction for CABG patients treated with 125 units. Moreover, those aged 65 and older showed a 51% risk reduction. The study also reported lower 30-day rehospitalization rates (8.7% vs. 15.7%) and more patients being atrial fibrillation-free (62.9% vs. 45.1%). Adverse events were similar across treatment groups, highlighting AGN-151607's potential in specific populations.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), expands its Pink Ribbon Strong 365 campaign, dedicated to year-round support for breast cancer patients, survivors, and previvors. The initiative emphasizes education and empowerment, offering resources like the Natrelle Cares Package and the Natrelle Inspires Bra, which donates one bra for every purchase. The campaign also includes an award-winning documentary and partnerships with organizations like METAvivor. Allergan aims to raise awareness and provide comprehensive support beyond Breast Cancer Awareness Month.
Genmab has submitted a Biologics License Application (BLA) to the U.S. FDA for epcoritamab, a bispecific antibody targeting relapsed/refractory large B-cell lymphoma. AbbVie has also validated a Marketing Authorization Application (MAA) for epcoritamab with the European Medicines Agency (EMA). These submissions stem from the EPCORE NHL-1 phase 2 trial, showing the drug's safety and efficacy in treating CD20+ mature B-cell non-Hodgkin lymphoma, a significant medical need exists for these patients. The joint development with AbbVie aims to bring new therapeutic options to market.
AbbVie (NYSE: ABBV) has announced the validation of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for epcoritamab, an investigational treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Concurrently, Genmab has submitted a Biologics License Application (BLA) to the FDA for the same drug. Epcoritamab is supported by results from the EPCORE™ NHL-1 Phase 2 trial and aims to address significant unmet needs in treating B-cell malignancies. This joint effort highlights AbbVie's commitment to advancing oncology care.
AbbVie reported third-quarter results for 2022, showing a 24.2% increase in diluted EPS to $2.21 on a GAAP basis, and adjusted diluted EPS of $3.66, up 29.3%. Total net revenues reached $14.812 billion, reflecting a 3.3% increase. The immunology portfolio delivered $7.651 billion, a 14.6% rise, bolstered by Skyrizi and Rinvoq. However, Humira sales decreased internationally by 25.9% due to competition. The company also announced a 5.0% dividend increase, raising the quarterly dividend to $1.48 per share.
AbbVie announced the presentation of 26 abstracts at the ACG Annual Scientific Meeting from October 21-26, 2022, focusing on its gastroenterology portfolio. Key topics include Crohn's disease treatment outcomes from the SKYRIZI pivotal program and insights on CREON's effects on exocrine pancreatic insufficiency. Presentations aim to enhance understanding of digestive disorders and support patients with high unmet needs. The meeting highlights AbbVie’s commitment to advancing research in inflammatory bowel diseases and improving standards of care.
AbbVie announced FDA approval for RINVOQ (upadacitinib) as the first oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA). This follows its earlier approval for ankylosing spondylitis (AS), marking RINVOQ as the only JAK inhibitor for both conditions. In clinical trials, nearly 45% of nr-axSpA patients on RINVOQ achieved significant disease control at week 14, outperforming placebo. AbbVie aims to enhance treatment options for patients with chronic, painful diseases.
